The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development
Frontiers in Pharmacology · 10.04.2026 · 17
DOI: 10.3389/fphar.2026.1699987 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.04.2026. Verfasst von Emad M Abdallah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, College of Science, Qassim University, Buraydah, Saudi Arabia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 248 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antimicrobial resistance (AMR) remains one of the most serious global threats to public health, driven by the rapid emergence and dissemination of multidrug-resistant bacterial pathogens that compromise existing antibiotic therapies. In response, the World Health Organization (WHO) has defined priority lists of antibiotic-resistant bacteria to guide research, innovation, and drug development efforts. This narrative review synthesizes current knowledge on the molecular mechanisms underlying resistance in WHO-priority pathogens, including reduced membrane permeability, efflux pump overexpression, enzymatic drug inactivation, target modification, biofilm formation, and horizontal gene transfer. Beyond mechanistic insights, we critically evaluate the therapeutic limitations of conventional antibiotics, the failure of traditional discovery pipelines, and the growing clinical and economic burden of resistant infections. Emerging strategies, including artificial intelligence-assisted drug discovery, phage therapy, antimicrobial peptides, CRISPR-based systems, resistance-modifying combinations, and natural product-derived compounds and plant compounds, are assessed with emphasis on pharmacological feasibility, translational challenges, and clinical relevance. Particular attention is given to issues of delivery, toxicity, dosing optimization, resistance emergence, regulatory barriers, and real-world implementation. Finally, we highlight the central role of antimicrobial stewardship, surveillance, and a One Health framework integrating human, animal, and environmental sectors in mitigating resistance and sustaining therapeutic effectiveness. Collectively, this review underscores that addressing WHO-priority pathogens will require integrated, multidisciplinary strategies that bridge molecular biology, pharmacology, clinical translation, and public health.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biology, College of Science, Qassim University, Buraydah, Saudi Arabia.
- Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
- Faculty of Pharmacy, University of Malaya, Wilayah PersekutuanKuala Lumpur, Malaysia.
- Department of Chemistry and Biochemistry, Kennesaw State University, Kennesaw, GA, United States.
- School of Pharmacy, BRAC University, Dhaka, Bangladesh.
- Biotechnology program, Department of Mathematics and Natural Science, BRAC University, Dhaka, Bangladesh.
Zitieren
APA
Abdallah, E. M., Alhudhaibi, A. M., Dahab, M., Al Noman, A., Sharma, P. D., Taha, T. H., & Nawaz, M. (2026). The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1699987
Vancouver
Abdallah EM, Alhudhaibi AM, Dahab M, Al Noman A, Sharma PD, Taha TH, et al. The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1699987
BibTeX
@article{Abdallah2026,
author = {Abdallah, Emad M and Alhudhaibi, Abdulrahman Mohammed and Dahab, Mahmoud and Al Noman, Abdullah and Sharma, Pranab Dev and Taha, Tarek H and Nawaz, Muhammad},
title = {The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1699987}
}
EUVIMED